The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.
GSK and the US Department of Health and Human Services inked a deal to fund development of new antibiotics, an area where clinicians face a dearth of new options.
CMPMedica ceased publication on two of its titles--Infections in Medicine and AIDS Reader--due to a continuing decline in print advertising sales.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.